Recursion Pharmaceuticals (RXRX) Total Liabilities (2020 - 2026)

Recursion Pharmaceuticals has reported Total Liabilities for 7 years, with the latest figure at $314.8 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities fell 15.23% year-over-year to $314.8 million; the trailing twelve-month figure through Mar 2026 stood at $314.8 million (down 15.23% YoY), and the FY2025 full-year result was $343.3 million, down 17.05% from the prior year.
• Total Liabilities for Q1 2026 stood at $314.8 million, down from $343.3 million in the prior quarter.
• The five-year high for Total Liabilities was $413.8 million in Q4 2024, with the low at $156.7 million in Q1 2024.
• Historically, Total Liabilities has averaged $260.1 million across 5 years, with a median of $223.5 million in 2022.
• Annual changes were most pronounced in 2022 — Total Liabilities jumped 324.89% — and 2024, when it dropped 20.54%.
• Recursion Pharmaceuticals' Total Liabilities stood at $215.5 million in 2022, then declined by 11.7% to $190.3 million in 2023, then surged by 117.5% to $413.8 million in 2024, then declined by 17.05% to $343.3 million in 2025, then declined by 8.31% to $314.8 million in 2026.
• The last three Total Liabilities figures came in at $314.8 million (Q1 2026), $343.3 million (Q4 2025), and $352.6 million (Q3 2025), per Business Quant data.